Preclinical trauma studies of recombinant factor VIIa

Martin Schreiber, John B. Holcomb, Rasmus Rojkjaer

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    Preclinical studies in animals and ex vivo human blood have provided a solid rationale for conducting prospective randomized trials in trauma patients. Small animal models have been utilized to study the efficacy of recombinant activated factor VII (rFVIIa; NovoSeveng®) in treating thrombocytopenic rabbits and for the reversal of anticoagulation. Safety models in the rabbit also exist to test for systemic activation of clotting and pathologic thrombosis. Animal models simulating traumatic injuries in humans have primarily been performed in pigs because of species similarities in terms of coagulation characteristics and the larger internal organs. The pig studies, utilizing human rFVIIa, have shown increased strength of clot formation, decreased bleeding, and improved survival. However, these findings are not uniform and are dependant on the model chosen. All of the animal models described have provided good safety data and suggest that the use of rFVIIa is not associated with systemic activation of coagulation or microthrombosis of end organs.

    Original languageEnglish (US)
    JournalCritical Care
    Volume9
    Issue numberSUPPL. 5
    DOIs
    StatePublished - Oct 2005

    Fingerprint

    Animal Models
    Wounds and Injuries
    Swine
    Rabbits
    Safety
    Factor VIIa
    Thrombosis
    Hemorrhage
    Survival
    recombinant FVIIa

    ASJC Scopus subject areas

    • Critical Care and Intensive Care Medicine

    Cite this

    Preclinical trauma studies of recombinant factor VIIa. / Schreiber, Martin; Holcomb, John B.; Rojkjaer, Rasmus.

    In: Critical Care, Vol. 9, No. SUPPL. 5, 10.2005.

    Research output: Contribution to journalArticle

    Schreiber, Martin ; Holcomb, John B. ; Rojkjaer, Rasmus. / Preclinical trauma studies of recombinant factor VIIa. In: Critical Care. 2005 ; Vol. 9, No. SUPPL. 5.
    @article{65485f81167d4ebd9f00c396f4ec1fef,
    title = "Preclinical trauma studies of recombinant factor VIIa",
    abstract = "Preclinical studies in animals and ex vivo human blood have provided a solid rationale for conducting prospective randomized trials in trauma patients. Small animal models have been utilized to study the efficacy of recombinant activated factor VII (rFVIIa; NovoSeveng{\circledR}) in treating thrombocytopenic rabbits and for the reversal of anticoagulation. Safety models in the rabbit also exist to test for systemic activation of clotting and pathologic thrombosis. Animal models simulating traumatic injuries in humans have primarily been performed in pigs because of species similarities in terms of coagulation characteristics and the larger internal organs. The pig studies, utilizing human rFVIIa, have shown increased strength of clot formation, decreased bleeding, and improved survival. However, these findings are not uniform and are dependant on the model chosen. All of the animal models described have provided good safety data and suggest that the use of rFVIIa is not associated with systemic activation of coagulation or microthrombosis of end organs.",
    author = "Martin Schreiber and Holcomb, {John B.} and Rasmus Rojkjaer",
    year = "2005",
    month = "10",
    doi = "10.1186/cc3782",
    language = "English (US)",
    volume = "9",
    journal = "Critical Care",
    issn = "1364-8535",
    publisher = "BioMed Central Ltd.",
    number = "SUPPL. 5",

    }

    TY - JOUR

    T1 - Preclinical trauma studies of recombinant factor VIIa

    AU - Schreiber, Martin

    AU - Holcomb, John B.

    AU - Rojkjaer, Rasmus

    PY - 2005/10

    Y1 - 2005/10

    N2 - Preclinical studies in animals and ex vivo human blood have provided a solid rationale for conducting prospective randomized trials in trauma patients. Small animal models have been utilized to study the efficacy of recombinant activated factor VII (rFVIIa; NovoSeveng®) in treating thrombocytopenic rabbits and for the reversal of anticoagulation. Safety models in the rabbit also exist to test for systemic activation of clotting and pathologic thrombosis. Animal models simulating traumatic injuries in humans have primarily been performed in pigs because of species similarities in terms of coagulation characteristics and the larger internal organs. The pig studies, utilizing human rFVIIa, have shown increased strength of clot formation, decreased bleeding, and improved survival. However, these findings are not uniform and are dependant on the model chosen. All of the animal models described have provided good safety data and suggest that the use of rFVIIa is not associated with systemic activation of coagulation or microthrombosis of end organs.

    AB - Preclinical studies in animals and ex vivo human blood have provided a solid rationale for conducting prospective randomized trials in trauma patients. Small animal models have been utilized to study the efficacy of recombinant activated factor VII (rFVIIa; NovoSeveng®) in treating thrombocytopenic rabbits and for the reversal of anticoagulation. Safety models in the rabbit also exist to test for systemic activation of clotting and pathologic thrombosis. Animal models simulating traumatic injuries in humans have primarily been performed in pigs because of species similarities in terms of coagulation characteristics and the larger internal organs. The pig studies, utilizing human rFVIIa, have shown increased strength of clot formation, decreased bleeding, and improved survival. However, these findings are not uniform and are dependant on the model chosen. All of the animal models described have provided good safety data and suggest that the use of rFVIIa is not associated with systemic activation of coagulation or microthrombosis of end organs.

    UR - http://www.scopus.com/inward/record.url?scp=31744442797&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=31744442797&partnerID=8YFLogxK

    U2 - 10.1186/cc3782

    DO - 10.1186/cc3782

    M3 - Article

    C2 - 16221316

    AN - SCOPUS:31744442797

    VL - 9

    JO - Critical Care

    JF - Critical Care

    SN - 1364-8535

    IS - SUPPL. 5

    ER -